Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.
Al-Khatib
S M
SM
Duke Clinical Research Institute, Durham, North Carolina 27715, USA. alkha001@mc.duke.edu
Pieper
K S
KS
Lee
K L
KL
Mahaffey
K W
KW
Hochman
J S
JS
Pepine
C J
CJ
Kopecky
S L
SL
Akkerhuis
M
M
Stepinska
J
J
Simoons
M L
ML
Topol
E J
EJ
Califf
R M
RM
Harrington
R A
RA
D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality*; D004311:Double-Blind Method; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016016:Proportional Hazards Models; D020521:Stroke / Q000209:etiology / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide